Shionogi, J&J deal

Shionogi disclosed in its first quarter earnings for the period ended June 30, that Johnson & Johnson returned worldwide rights to Doribax doripenem in June. J&J had worldwide rights to Doribax, excluding Japan, where Shionogi markets the product as Finibax. The companies could not be reached for details. ...